Novo Nordisk A/S (NVO) Receiving Somewhat Positive News Coverage, Analysis Shows

News articles about Novo Nordisk A/S (NYSE:NVO) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm ranks the sentiment of media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Novo Nordisk A/S earned a media sentiment score of 0.18 on Accern’s scale. Accern also gave news coverage about the company an impact score of 46.0804712265824 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

These are some of the news articles that may have impacted Accern Sentiment’s scoring:

Shares of Novo Nordisk A/S (NYSE:NVO) traded up $0.25 during trading hours on Friday, reaching $54.74. The company had a trading volume of 645,393 shares, compared to its average volume of 839,702. Novo Nordisk A/S has a 12 month low of $32.83 and a 12 month high of $54.76. The firm has a market cap of $139,587.00, a price-to-earnings ratio of 23.90, a P/E/G ratio of 3.06 and a beta of 0.63.

Several research firms have recently commented on NVO. Zacks Investment Research raised Novo Nordisk A/S from a “hold” rating to a “buy” rating and set a $60.00 price target for the company in a research report on Tuesday, January 2nd. JPMorgan Chase & Co. raised Novo Nordisk A/S from an “underweight” rating to a “neutral” rating in a research report on Friday, December 29th. Bank of America raised Novo Nordisk A/S from a “neutral” rating to a “buy” rating in a research report on Wednesday, December 6th. Morgan Stanley raised Novo Nordisk A/S from an “equal weight” rating to an “overweight” rating in a research report on Friday, December 1st. Finally, BNP Paribas lowered Novo Nordisk A/S from an “outperform” rating to a “neutral” rating in a research report on Monday, September 25th. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $60.00.

In other Novo Nordisk A/S news, insider Eric S. Sprott bought 50,000 shares of Novo Nordisk A/S stock in a transaction that occurred on Wednesday, November 8th. The shares were bought at an average cost of $8.34 per share, with a total value of $417,000.00. Corporate insiders own 0.07% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Novo Nordisk A/S (NVO) Receiving Somewhat Positive News Coverage, Analysis Shows” was posted by Community Financial News and is owned by of Community Financial News. If you are viewing this report on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The original version of this report can be accessed at

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company’s diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs.

Insider Buying and Selling by Quarter for Novo Nordisk A/S (NYSE:NVO)

What are top analysts saying about Novo Nordisk A/S? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Novo Nordisk A/S and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit